CGS 16617

Known as: CGS-16617 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
The effects of six angiotensin converting enzyme inhibitors (captopril, CGS-16617, cilazapril, enalapril, utibapril, and… (More)
Is this relevant?
1990
1990
The effects of angiotensin-converting enzyme inhibitors on cardiovascular mass and function were measured in three groups of 22… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
1989
1989
SummaryA new, orally active angiotensin converting enzyme (ACE) inhibitor, CGS 16617, has been evaluated in normotensive subjects… (More)
Is this relevant?
1989
1989
The disposition and metabolism of CGS 16617 (3-[(5-amino-1-carboxy-1S-pentyl)amino],2,3,4,5-tetrahydro-2-oxo-3S-1H-1… (More)
Is this relevant?
1988
1988
Renal actions of the new angiotensin converting enzyme inhibitor CGS 16617 were evaluated in anesthetized dogs. Intravenous… (More)
Is this relevant?
1987
1987
A specific inhibitor of thromboxane A2 (TxA2) synthesis, CGS-12970, a new angiotensin-converting enzyme (ACE) inhibitor, CGS… (More)
Is this relevant?
1987
1987
The effect of a specific inhibitor of thromboxane (Tx) A2 synthesis, CGS-13080, a new angiotensin converting enzyme inhibitor… (More)
Is this relevant?
1985
1985
Pentopril (CGS 13945) was administered in 125-mg capsules to eight healthy men on two occasions according to a randomized… (More)
Is this relevant?
1985
1985
CGS 16617, a direct-acting angiotensin-converting-enzyme inhibitor, was administered as a single dose of 20 mg in aqueous… (More)
Is this relevant?